Krystal Biotech (KRYS) AI Stock Analysis

• Market Cap: $3.99B
• Dividend Yield: N/A
• Average Volume (3M): 374.11K
• Price to Earnings (P/E): 33.6
• Beta (1Y): 0.81
• Revenue Growth: 247.53%
• EPS Growth: 118.34%
• Country: US
• Employees: 275
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): 1.20
• Shares Outstanding: 28,898,680
• 10 Day Avg. Volume: 290,783
• 30 Day Avg. Volume: 374,108
• PEG Ratio: -0.19
• Price to Book (P/B): 3.87
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.15
• Enterprise Value/Market Cap: 0.47
• Enterprise Value/Revenue: 1.81
• Enterprise Value/Gross Profit: 6.04
• Enterprise Value/Ebitda: 6.32
• 1Y Price Target: $196.14
• Price Target Upside: 40.48% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 71 Outperform
• Price Target: $139.00 ▼(-0.44%Downside)

Krystal Biotech's stock score is primarily driven by its strong financial performance and positive outlook from recent earnings and corporate events. However, technical indicators suggest bearish momentum, and the valuation is moderate, balancing the overall score.

Positive Factors

Market Expansion

The company reiterated confidence in reaching the 1,200 identified patients for Vyjuvek.

Regulatory Progress

KRYS received a positive CHMP opinion for Vyjuvek for the treatment of wounds in DEB patients from birth.

Therapy Efficacy

The transition to maintenance phase usage for Vyjuvek reflects its efficacy, as many patients are enjoying the benefits of wound closure.

Negative Factors

Market Dynamics

The peak US Vyjuvek is lowered to ~$500M from ~$700M, indicating moderated dynamics in the US market.

Patient Acquisition

Achieving the target of ~700 US Vyjuvek patients will take longer than anticipated.

Krystal Biotech Business Overview & Revenue Model

Company Description

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

How the Company Makes Money

Krystal Biotech primarily makes money through the development and commercialization of its gene therapy products. Revenue is generated from product sales, particularly as its lead candidate, B-VEC, progresses through clinical trials and gains regulatory approval for commercialization. Additionally, the company may enter into strategic partnerships and collaborations with other pharmaceutical companies to co-develop or license its technology, which can provide milestone payments and royalties. While Krystal Biotech currently focuses on advancing its clinical pipeline, future revenues may also come from expanding its product offerings and entering new markets within the genetic medicine sector.

Krystal Biotech Financial Statement Overview

Summary

Krystal Biotech has demonstrated strong financial performance with notable revenue growth, a high gross profit margin, and a significant turnaround to profitability. The balance sheet shows low leverage and strong equity use, while cash flow generation has improved, enhancing financial flexibility.

Income Statement

Krystal Biotech has shown impressive financial performance with a significant increase in total revenue from $50.7 million in 2023 to $290.5 million in 2024, indicating a strong revenue growth rate. The gross profit margin is robust at 93.1% for 2024, and the net profit margin stands at 30.7%, reflecting high profitability. Despite earlier losses, the company has turned profitable, with both EBIT and EBITDA margins improving significantly.

Balance Sheet

The balance sheet shows a solid equity position with a debt-to-equity ratio of 0.008, indicating low leverage risk. The return on equity is 9.4%, reflecting efficient use of equity to generate profits. The equity ratio is high at 89.6%, suggesting a strong capital structure with a majority of assets financed by equity.

Cash Flow

The cash flow analysis reveals a positive turnaround with a free cash flow of $119.2 million in 2024 compared to negative figures in previous years. The operating cash flow to net income ratio is 1.38, indicating effective cash generation relative to net income. The company has managed to sustain positive cash flow, enhancing its financial flexibility.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
333.45M	290.51M	50.70M	0.00	0.00	0.00
	Gross Profit
308.79M	270.45M	47.60M	-4.05M	-2.77M	-1.85M
	EBIT
121.06M	65.69M	-109.73M	-145.20M	-68.28M	-33.00M
	EBITDA
130.03M	109.91M	17.90M	-145.20M	-65.31M	-30.32M
	Net Income Common Stockholders
123.96M	89.16M	10.93M	-139.97M	-69.57M	-32.17M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
616.85M	597.52M	532.18M	379.17M	438.10M	271.26M
	Total Assets
1.07B	1.06B	818.36M	558.45M	626.29M	310.84M
	Total Debt
9.66M	7.26M	8.09M	8.93M	8.02M	11.55M
	Net Debt
-299.11M	-337.60M	-350.23M	-152.97M	-333.22M	-256.72M
	Total Liabilities
89.74M	109.46M	39.71M	36.22M	32.72M	18.76M
	Stockholders Equity
984.67M	946.38M	778.64M	522.23M	593.58M	292.08M
Cash Flow		Free Cash Flow
129.32M	119.18M	-100.60M	-153.55M	-116.27M	-40.93M
	Operating Cash Flow
138.50M	123.42M	-88.80M	-100.57M	-47.94M	-26.08M
	Investing Cash Flow
-192.23M	-163.44M	82.64M	-114.08M	-226.77M	-11.18M
	Financing Cash Flow
3.96M	27.01M	202.75M	35.35M	347.69M	118.02M

Krystal Biotech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 139.62
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRYS, the sentiment is Negative. The current price of 139.62 is above the 20-day moving average (MA) of 130.32, below the 50-day MA of 149.17, and below the 200-day MA of 169.11, indicating a neutral trend. The MACD of -3.22 indicates Negative momentum. The RSI at 53.25 is Neutral, neither overbought nor oversold. The STOCH value of 88.71 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KRYS.

Krystal Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KRYS	71 Outperform	$3.99B	33.62	13.90%	―	247.53%	118.34%
VRNA	68 Neutral	$7.39B	―	-72.73%	―	―	-157.53%
SRPT	56 Neutral	$3.84B	19.61	-23.61%	―	59.15%	-1881.09%
AXSM	55 Neutral	$5.41B	―	-282.16%	―	72.16%	9.65%
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
BPMC	50 Neutral	$8.28B	―	-47.71%	―	99.19%	48.43%
CYTK	42 Neutral	$4.13B	―	435.49%	―	412.21%	1.75%

Krystal Biotech Corporate Events

Krystal Biotech Reports Promising Results for KB707 Trial

On June 2, 2025, Krystal Biotech presented a clinical update on its Phase 1/2 trial of inhaled KB707, a novel HSV-based immunotherapy for advanced lung tumors, at the ASCO Annual Meeting. The study showed that KB707 was safe, well-tolerated, and demonstrated promising anti-tumor effects, with a 36% objective response rate in heavily pre-treated non-small cell lung cancer patients. The results suggest potential synergy with immune checkpoint inhibitors, and further evaluation is ongoing.

The most recent analyst rating on (KRYS) stock is a Buy with a $208.00 price target. To see the full list of analyst forecasts on Krystal Biotech stock, see the KRYS Stock Forecast page.

Krystal Biotech Holds Annual Stockholders Meeting

On May 16, 2025, Krystal Biotech held its Annual Meeting of Stockholders where key decisions were made, including the election of Class II directors and the ratification of KPMG LLP as the independent registered public accounting firm for 2025. Additionally, stockholders approved the compensation of the company’s named executive officers for the fiscal year 2024, reflecting confidence in the company’s leadership and strategic direction.

The most recent analyst rating on (KRYS) stock is a Buy with a $208.00 price target. To see the full list of analyst forecasts on Krystal Biotech stock, see the KRYS Stock Forecast page.

Krystal Biotech Expands Gene Therapy Platform

On May 9, 2025, Krystal Biotech presented a poster at the Society for Investigative Dermatology Annual Meeting, detailing the expansion of its HSV-1-based gene therapy platform to treat Hailey-Hailey and Darier diseases. The studies demonstrated that the company’s gene therapy vectors, KB111 and KB112, can effectively transduce keratinocytes and express ATPases with minimal toxicity, indicating promising potential for treating these rare skin conditions.

The most recent analyst rating on (KRYS) stock is a Buy with a $208.00 price target. To see the full list of analyst forecasts on Krystal Biotech stock, see the KRYS Stock Forecast page.

Krystal Biotech Presents Promising Gene Therapy at ARVO

On May 5, 2025, Krystal Biotech presented research at the ARVO Annual Meeting showcasing their HSV-1-based gene therapy vector, KB801, which demonstrated sustained nerve growth factor expression in wounded murine corneas. This development highlights KB801’s potential as a safe and effective topical treatment for neurotrophic keratitis, offering a less burdensome alternative to the current treatment, cenegermin-bkbj, which requires frequent dosing.

Krystal Biotech Gains EU Approval for VYJUVEK®

On April 23, 2025, the European Commission approved VYJUVEK® for treating dystrophic epidermolysis bullosa (DEB) in Europe, marking it as the first corrective medicine for DEB in the region. This approval allows flexible dosing at home or in healthcare settings and is expected to significantly impact Krystal Biotech‘s market presence in Europe, with plans for a launch in Germany by mid-2025.